Still not profitable yet involved in multiple patent lawsuits, Yifang Bio claims that it is not involved in the research pipeline.

① Yifang Biotechnology and its controlling person are involved in a patent infringement lawsuit, being asked to pay 99 million yuan. Yifang Biotechnology's revenue for the first three quarters of 2024 is less than 20 million yuan, and it has not yet achieved profitability; ② Company personnel stated that the lawsuit targets some patents related to Yifang Biotechnology's intellectual property and does not involve the research pipeline.

cls.cnDec 25 14:57

Selling ATU's USA and United Kingdom Business, the strategy behind WUXI APPTEC.

There is gain in loss.

wallstreetcnDec 25 10:26

The pig industry is undergoing changes! "Cost reduction" has become the key to success or failure. Are publicly listed pig companies experiencing better-than-expected profit improvements?

Under the dual effect of rising Pork prices and falling costs, the profitability of listed pig farming companies is rapidly improving.

Zhitong FinanceDec 11 21:21

Jiangsu Hengrui Pharmaceuticals plans to list in Hong Kong! The hundred billion yuan pharmaceutical company ranks first among heavyweight in fund stocks in the A-share pharmaceutical sector.

On December 9, Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that, after the approval of the board of directors, in order to further assist the company's international business development, the company plans to issue shares (listed in hong kong) overseas and list on the main board of the Hong Kong Stock Exchange.

brokerage chinaDec 10 07:53

0.15 billion! Wuxi AppTec invested in a French VC, adding to the European biomedical market.

① Wuxi Apptec plans to invest in the "Jeito II S.L.P." fund, with a total target scale not exceeding 1.2 billion euros, and the fund is expected to invest in 14-17 medical innovative startups. ② Previously, Wuxi Apptec planned to invest 10 million euros in another well-known biotechnology investment institution in Europe, focusing on early-stage biomedical companies in Europe.

cls.cnDec 9 18:34

The chapter comes to a close! The final version of the NDAA in both the House and Senate did not include the biological security bill. Will it make a comeback next year?

1. The final negotiation text of NDAA did not include the "Biosecurity Act", and the attempt to "ride on the coattails" failed again; 2. This year, the session of the US Congress will come to an end, experts believe that the legislation of the "Biosecurity Act" this year may come to a conclusion, but it may "come back with a vengeance" next year.

cls.cnDec 9 07:33